Actinogen Medical Share Price and Company Fundamentals
Last traded: Today at 6:10 AM
Actinogen Medical Limited, a biotechnology company, develops therapies for cognitive impairment associated with chronic neurological, psychiatric, and metabolic diseases in Australia. The company is developing Xanamem, a therapy for Alzheimer's disease, and cognitive impairment associated with schizophrenia, diabetes, and other disorders; and XanADu, which has completed Phase II clinical trials is a double-blind, randomized, and placebo-controlled study to assess the safety, tolerability, and efficacy of Xanamem in subjects with mild Alzheimer's disease. It is also developing XanaHES, a single blinded, central reader blinded, placebo-controlled, and dose escalation study of Xanamem to assess safety and tolerability in healthy elderly subjects. The company was formerly known as Actinogen Limited and changed its name to Actinogen Medical Limited in November 2015. Actinogen Medical Limited was incorporated in 1999 and is headquartered in Sydney, Australia.
|Primary activities||Development and commercialisation of new therapeutic compounds|
|Industry / Sector||Biotechnology / Healthcare|
|Mailing address||109 Pitt Street Suite 901 Level 9 Sydney NSW 2000 Australia|
|Phone / Fax||61 2 8964 7401 / 61 2 8964 7588|
|Share registry||LINK MARKET SERVICES LIMITED|
Actinogen Medical does not pay dividends.
As of May 2021, following are the company executives and directors listed on Actinogen Medical.
|Dr. Steven G. Gourlay||MD, CEO & Director||60|
|Mr. Jeff Carter||Chief Financial Officer||62|
|Mr. Peter Gordon Webse M.A.I.C.D., B.Bus, FGIA, FCIS, FCPA, MAICD||Company Sec.||57|
Profitability and management effectiveness
Return on assets
Return on equity
Profitability ratios are a class of financial metrics that are used to assess a business's ability to generate earnings relative to its revenue, operating costs, balance sheet assets, and shareholders' equity over time, using data from a specific point in time.
The return on equity signifies how well the management is running the company in terms of capital management. The ideal return on equity is greater than 10%. The return on equity is calculated as net income divided by total share holders equity.
Valuation and Trading Info
The market capitalization of Actinogen Medical is 88.01M and its enterprise value is 64.33M. The enterprise value to revenue ratio of ACW is 22.62.
The ACW's stocks Beta value is 2.33 making it 133% more volatile compared to ASX market index. Technology stocks and small caps tend to have higher betas than the market benchmark. This indicates that adding the stock to a portfolio will increase the portfolio’s risk, but also increase its expected return. On the other hand utility stocks often have low betas because they tend to move more slowly than market averages.
Companies similar to Actinogen Medical (ACW)
Actinogen Medical (ASX:ACW) Frequently Asked Questions
1. What is Actinogen Medical's Stock Symbol?
Actinogen Medical trades on ASX under the ticker symbol "ACW".
2. What is Actinogen Medical's stock price today?
One share of ACW stock can currently be purchased for approximately $0.053.
3. How can I contact Actinogen Medical?
Actinogen Medical's mailing address is 109 Pitt Street Suite 901 Level 9 Sydney NSW 2000 Australia. The company can be reached via phone at 61 2 8964 7401.
4. What is Actinogen Medical's official website?
The official website of Actinogen Medical is http://www.actinogen.com.au.
5. Which share registry manages Actinogen Medical's stock?
Actinogen Medical's stock is managed by LINK MARKET SERVICES LIMITED.